Company Overview - Steris shares have decreased by approximately 1.8% over the past month, underperforming the S&P 500 [1] - The most recent earnings report is crucial for understanding the key drivers affecting the stock [1] Earnings Estimates - Estimates for Steris have trended downward in the past month, indicating a negative outlook [2][4] - The stock currently holds a Zacks Rank 3 (Hold), suggesting an expectation of in-line returns in the upcoming months [4] VGM Scores - Steris has an average Growth Score of C, a Momentum Score of C, and a Value Score of C, placing it in the middle 20% for investment strategies [3] Industry Performance - Steris is part of the Zacks Medical - Instruments industry, where Pacific Biosciences of California (PACB) has seen a gain of 11.3% over the past month [5] - Pacific Biosciences reported revenues of $37.15 million for the last quarter, reflecting a year-over-year decline of 4.3% [5] - The expected loss for Pacific Biosciences in the current quarter is $0.18 per share, with a year-over-year improvement of 10% [6]

Business Segments and Revenue - STERIS operates in three reportable business segments: Healthcare, Applied Sterilization Technologies (AST), and Life Sciences, with the majority of revenues derived from healthcare and medical device customers[11]. - For the year ended March 31, 2025, no customer represented more than 10% of total revenues in any of the segments[17][21][26]. - As of March 31, 2025, the company reported a backlog of $452.9 million, with $369.2 million related to the Healthcare segment and $83.7 million to the Life Sciences segment, indicating an increase from $425.2 million in the previous year[49][50]. - Healthcare segment revenue increased to $12,341 million in fiscal 2025 from $11,419 million in fiscal 2024, representing an increase of 8.1%[78]. - Revenues increased by $320.8 million, or 6.2%, to $5,459.5 million for the year ended March 31, 2025, compared to $5,138.7 million for the year ended March 31, 2024[205]. Research and Development - STERIS invests significantly in research and development to discover and market innovative, cost-effective products and services[45]. - The company has 607 U.S. patents and 2,315 patents in other jurisdictions, with 90 U.S. patent applications and 289 applications pending[31]. Operational Performance and Costs - STERIS experienced a rise in supply chain and labor costs during fiscal 2023 and 2024, which moderated in fiscal 2025[29]. - The company applies Lean principles across its operations to enhance performance, agility, and value[34]. - The average number of employees during fiscal 2025 was approximately 18,000, with less than 11% represented by work councils or labor unions, indicating generally good employee relations[77]. - Total employees rose to 17,787 in fiscal 2025, up from 16,768 in fiscal 2024, reflecting a growth of 6.1%[78]. - Total employee costs increased to $1,850,544 thousand in fiscal 2025 from $1,718,164 thousand in fiscal 2024, marking a rise of 7.7%[86]. - The company maintained zero Class I recalls in fiscal 2025, 2024, or 2023, demonstrating strong compliance with safety standards[89]. Environmental and Sustainability Efforts - The company has made significant investments to comply with environmental laws and regulations, focusing on improving energy and water efficiency and reducing waste[69]. - The company tracks greenhouse gas emissions and reports direct and indirect energy use, participating in the Carbon Disclosure Project[70]. - The company has developed new products aimed at reducing environmental impact, such as ultra-concentrate cleaning chemistries that offer 10 times the uses per container[71]. - The company has established key performance indicators aligned with Sustainability Accounting Standards Board (SASB) Standards for Medical Equipment & Supplies, focusing on financial materiality in sustainability reporting[56]. - STERIS has three facilities accredited to ISO 14001 and ISO 45001 standards, reflecting commitment to environmental management[82]. Regulatory and Compliance Challenges - STERIS is subject to extensive governmental regulations, which require compliance and can significantly impact operations and costs[38][39]. - The company faces extensive regulatory requirements for product approvals, and delays in obtaining these could harm revenues and profitability[106]. - Compliance with international laws and regulations may be burdensome and expensive, impacting operational efficiency[103]. - Regulatory changes regarding greenhouse gas emissions and sustainability reporting may impose additional compliance costs and risks of non-compliance[138]. - The company's EO sterilization operations are at risk from regulatory actions that could significantly affect operational costs and demand for medical devices[141]. Financial Position and Debt - As of March 31, 2025, STERIS had approximately $2,043.7 million of outstanding indebtedness, including $1,350.0 million of Senior Public Notes, $674.2 million of Private Placement Senior Notes, and $34.8 million under the Revolving Credit Facility[153]. - The debt-to-total capital ratio was 23.6% at March 31, 2025, indicating a stable capital structure[209]. - The company expects to continue paying cash dividends for the foreseeable future, as determined by its Board of Directors[187]. Acquisitions and Growth Strategy - Acquisitions are a key part of STERIS's long-term growth strategy, alongside organic opportunities[45]. - The company completed several tuck-in acquisitions during fiscal 2025, with total aggregate consideration of approximately $54.1 million, enhancing its Healthcare and AST segments[201]. - The acquisition of assets from Becton, Dickinson and Company was valued at $539.8 million, financed through borrowings from the existing credit facility[203]. - The company plans to sell its Dental segment for total cash consideration of $787.5 million, with potential additional payments based on revenue targets in fiscal 2025[205]. Employee Relations and Engagement - Employee turnover rate was 16% in fiscal 2025, slightly up from 15% in fiscal 2024, with a goal to achieve a rate of 10% or less[85]. - 88% of employees participated in the pulse survey in fiscal 2025, indicating strong engagement levels[85]. Cybersecurity and Risk Management - The company has implemented a cybersecurity risk management program integrated into its enterprise risk management (ERM) framework, with no material cyberattacks reported in fiscal year 2025[178]. - The company maintains a comprehensive incident response policy for managing cybersecurity incidents, overseen by an Executive Cybersecurity Steering Committee[173]. - The company may face increased cybersecurity risks due to reliance on IT systems and remote work arrangements[149]. Market and Competitive Environment - The competitive environment is intensifying, with increased competition from new products and technologies in infection prevention and sterile processing[128]. - Consolidations among healthcare customers may lead to pricing pressures and potential loss of customers[130]. - Geopolitical instability may lead to supply chain disruptions, increased production costs, and reduced consumer demand, potentially adversely affecting the company's business[102]. Legal and Liability Risks - The company is exposed to product liability claims, which could result in substantial costs and distract management from core responsibilities[110]. - Future litigation related to EO operations may increase costs and divert management attention, potentially impacting financial results[144]. - STERIS agreed to pay up to approximately $48.2 million to resolve claims related to EO exposure in Illinois[143].

STERIS' (STE) new acquisitions and partnerships strengthen its product offerings. The stock carries a Zacks Rank #2 (Buy) currently.Factors Driving STERIS' GrowthSTERIS’ Healthcare segment is gaining from the successful market adoption of its comprehensive offerings, including infection prevention consumables and capital equipment. Further, its services to maintain that equipment, repair reusable procedural instruments and outsource instrument reprocessing services are gaining traction. For the fourth quart ...

Dublin, May 20, 2025 (GLOBE NEWSWIRE) -- The "U.S. Gynecological Chairs and Tables Market Size, Share & Trends Analysis Report by Product (Gynecological Chairs, Gynecological Tables), Application (Urology Surgery, Pelvic Surgery), End-use, with Growth Forecasts, 2025-2030" report has been added to ResearchAndMarkets.com's offering.The U.S. Gynecological Chairs and Tables Market was valued at USD 194.8 Million in 2024, and is projected to reach USD 283.8 Million by 2030, rising at a CAGR of 6.50%. The expan ...

Have you evaluated the performance of Steris' (STE) international operations during the quarter that concluded in March 2025? Considering the extensive worldwide presence of this medical products maker, analyzing the patterns in international revenues is crucial for understanding its financial resilience and potential for growth.In today's increasingly interconnected global economy, a company's ability to tap into international markets can be a pivotal factor in shaping its overall financial health and grow ...

Since I upgraded to a Strong Buy rating on Steris plc (NYSE: STE ) in March 2025, the stock price has surged by more than 11%. I think Steris will potentially benefit from the TrumpAnalyst’s Disclosure: I/we have a beneficial long position in the shares of STE either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whos ...

STERIS (STE) Q4 2025 Earnings Call May 15, 2025 09:00 AM ET Company Participants Julie Winter - Vice President of Investor Relations & Corporate CommunicationsMichael Tokich - Senior VP & CFODaniel Carestio - President, CEO & DirectorPatrick Wood - Managing DirectorMac Etoch - Senior Research Associate Conference Call Participants David Turkaly - Research AnalystMike Matson - Senior Equity Research AnalystMichael Polark - Senior Equity Research AnalystJason Bednar - Senior Research AnalystBrett Fishbin - Vi ...

Financial Data and Key Metrics Changes - Total reported revenue grew by 4%, while constant currency organic revenue increased by 6% driven by volume and a 20 basis points price increase [6][10] - Gross margin increased by 170 basis points to 44.3%, with positive pricing, favorable mix, and productivity outpacing labor inflation [6][7] - EBIT margin rose by 110 basis points to 24.8% of revenue compared to the previous year [7] - Net income from continuing operations was $270 million, and adjusted earnings per diluted share increased by 14% to $2.74 [7][10] - Free cash flow for fiscal 2025 reached a record $787 million, significantly above guidance due to working capital improvements [8] Business Line Data and Key Metrics Changes - Healthcare constant currency organic revenue grew by 6% for the year, driven by strong recurring revenue streams, while capital equipment revenue declined by 5% [10][11] - Capital equipment orders grew over 12% for the full year, indicating strong underlying demand [11] - AST constant currency organic revenue grew by 9% for the year, with services growing by 7% [12] - Life Sciences saw a 1% increase in constant currency organic revenue, with margins improving to 42.3% [13] Market Data and Key Metrics Changes - The diversified nature of the business allowed the company to deliver results in line with original outlook despite obstacles [10] - The company anticipates revenue growth of 6% to 7% for fiscal 2026 across all segments, with a minor note on AST reflecting high single-digit growth in services [14][15] Company Strategy and Development Direction - The company plans to leverage its strengths to mitigate tariff exposure, with an estimated $30 million impact from tariffs included in the fiscal 2026 outlook [17][18] - The company is well-positioned to deliver both top and bottom line growth in 2026, with no acquisition or divestiture impacts expected [14][18] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the ability to deliver growth, particularly in recurring revenues and capital equipment orders, despite previous uncertainties in the pharma sector [23][24] - The anticipated tariff impact is expected to be managed strategically, with a focus on mitigating exposure through supply chain adjustments [18][62] Other Important Information - Capital expenditures for fiscal 2025 totaled $370 million, while depreciation and amortization amounted to $476 million [8] - The effective tax rate is planned at approximately 23.5% for fiscal 2026 [18] Q&A Session Summary Question: Comfort in Life Sciences bouncing back to 6% to 7% range - Management noted strong performance in recurring revenues, particularly in consumables, and a rebound in capital equipment orders towards the end of the year [23] Question: Impact of tariffs on EPS - Management discussed various headwinds and tailwinds, including $20 million in restructuring cost savings and lower interest expenses offsetting higher tax rates and tariff impacts [25][26] Question: Cash flow guidance differences - The anticipated $40 million legal settlement for ETO negatively impacts cash flow, along with tariffs and reduced inventory improvements [30] Question: M&A opportunities - Management indicated capacity for M&A from both financial and intellectual perspectives, should the right opportunity arise [32] Question: Onshoring trends - Management suggested that while there are opportunities for onshoring, regulatory complexities may limit rapid shifts in production [36][37] Question: AST growth expectations - Management expressed confidence in accommodating industry growth without capacity constraints [73] Question: Tariff breakdown and mitigation - Management confirmed that the $30 million tariff impact is a net number, with half attributed to China and half to global tariffs, and emphasized ongoing mitigation efforts [58][62]

STERIS plc (STE) reported fourth-quarter fiscal 2025 adjusted earnings per share (EPS) of $2.74, up 13.7% from the year-ago quarter’s figure. The figure surpassed the Zacks Consensus Estimate by 5.8%.The adjustment excludes the impacts of certain non-recurring charges, such as the amortization of acquired intangible assets and acquisition and integration-related charges.The company’s GAAP EPS was $1.48, down 3.9% from the year-ago level of $1.54.  Full-year fiscal 2025 adjusted EPS was $9.22, up 12.4% from ...

For the quarter ended March 2025, Steris (STE) reported revenue of $1.48 billion, up 4.3% over the same period last year. EPS came in at $2.74, compared to $2.41 in the year-ago quarter.The reported revenue compares to the Zacks Consensus Estimate of $1.48 billion, representing a surprise of -0.09%. The company delivered an EPS surprise of +5.79%, with the consensus EPS estimate being $2.59.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectati ...